[ Inglese] ASH 2017: Are Experts Personalizing Therapy to the Genetics of a Patient’s Myeloma?

Published on

Topics include: Treatments and Understanding

Where do things stand now with personalizing myeloma therapy to a patient’s genetic profile? At the American Society of Hematology (ASH) 2017 conference in Atlanta, Esther Schorr speaks with Dr. Gareth Morgan, Director of the UAMS Myeloma Institute, about new oncogenes in myeloma. They also discuss the importance of testing at the time of myeloma diagnosis to set a treatment plan. Watch for this top myeloma expert’s take on the latest myeloma research.

Produced by Patient Power. We thank AbbVie, Inc., Celgene and Takeda Oncology for their support.

View more programs featuring and

Produced in association with

Related Programs

ASH 2017 Myeloma Roundtable: Game-Changing Treatment Tools in Myeloma

A roundtable of esteemed myeloma experts including Dr. Carol Ann Huff, Dr. Sagar Lonial and Dr. Suzanne Lentzsch weigh in on the breaking news out of ASH 2017 for myeloma patients.


ASH 2017 Daily Wrap: Day Two

In day two of Patient Power’s daily wrap-up from ASH 2017, Andrew and Esther Schorr are joined by Dr. Mike Thompson, Dr. Mohit Trikha and patient advocate Cynthia Chmielewski.


Unisciti alla nostra comunità Registrati per eventi Leggi il nostro ultimo blog

Page last updated on December 20, 2017